PRP in Orthopedic Surgery
Reading File
Finding Sources
Searching PubMed
"platelet-rich plasma"[MeSH Terms] AND "orthopedic"[MeSH Terms]
Reading File
Reading File
Searching PubMed
"platelet-rich plasma" AND orthopedic surgery
Finding Sources
Reading Article
PMID: 38295392
Reading Article
PMID: 38037038
Reading File
Reading File
Searching PubMed
"platelet-rich plasma" AND tendinopathy
Reading Article
PMID: 40200209
Finding Sources
I now have comprehensive content from multiple authoritative sources. Let me compile the full, well-structured answer.
Platelet-Rich Plasma (PRP) in Orthopedic Surgery
What Is PRP?
PRP is an autologous blood product produced by centrifuging a patient's own blood to concentrate the platelet-enriched plasma fraction above baseline whole-blood values - typically achieving at least 4x the normal platelet concentration. The resulting solution is rich in numerous bioactive molecules:
- Growth factors: TGF-β (transforming growth factor-beta), PDGF (platelet-derived growth factor), FGF (fibroblast growth factor), VEGF (vascular endothelial growth factor), CTGF (connective tissue growth factor)
- Cytokines: Multiple interleukins (ILs)
- Other mediators: Analgesic, anti-inflammatory, and anti-degenerative molecules
Because it is autologous, PRP carries minimal immunologic risk.
- Rockwood and Green's Fractures in Adults, 10th ed. (2025), p. 86
Mechanism of Action
The original hypothesis was that concentrated growth factors directly stimulate tissue regeneration. More recent work suggests PRP induces a local inflammatory response in tendon tissue, which then triggers a regenerative cascade - a somewhat counterintuitive but important nuance. In OA and cartilage contexts, the key mediators may instead be analgesic and anti-degenerative.
Clinical Applications in Orthopedics
1. Tendinopathy (Chronic Tendon Disease)
This is the most studied orthopedic indication.
Evidence summary (2025 meta-analysis, 27 RCTs, n=1,779):
- Rotator cuff: At 1 month, PRP and corticosteroid (CS) show no significant difference. At 3 months, PRP demonstrates superior VAS pain reduction (OR = -1.64, 95% CI [-2.97, -0.31])
- Lateral epicondylitis (tennis elbow): CS is better at 1 month; PRP shows superior VAS and DASH scores at 3 and 12 months
- Plantar fasciitis: No difference at 1 and 3 months; PRP significantly better VAS and AOFAS scores at 6 months
- Tenosynovitis: CS superior at 1 month; PRP superior at 6 months
Key conclusion: PRP's mid-term efficacy (3-12 months) is superior to corticosteroids for most tendinopathies, but early (1-month) results often favor CS. Long-term data remain limited. (Ye et al., 2025, BMC Musculoskelet Disord, PMID: 40200209)
2. Acute Tendon Rupture (Achilles Tendon)
The evidence here is less favorable. A blinded RCT found that in non-surgically managed acute Achilles tendon rupture, PRP injection did not improve healing or function at 12 months compared with placebo (J Bone Joint Surg Am, 2021). Campbell's similarly notes that clinical results "remain equivocal" for PRP augmentation in acute Achilles repair.
- Campbell's Operative Orthopaedics, 15th ed. (2026), Chapter 53
3. Knee Osteoarthritis
This is the most clinically debated area, with the largest body of evidence.
Network meta-analysis (35 RCTs, n=3,104 patients):
- PRP showed the best WOMAC function scores at 3, 6, and 12 months vs. corticosteroids, hyaluronic acid (HA), or placebo
- PRP + HA combination showed the best VAS pain scores at 6 months
- No therapy, including PRP, caused a significant increase in adverse events vs. placebo
AAOS Technology Overview (2024) - based on 54 articles (36 high-quality, 18 moderate-quality) - reviewed PRP vs. control/placebo, NSAIDs, CS, HA, ozone therapy, prolotherapy, and bone marrow aspirate concentrate. The findings were summarized without a single definitive superiority claim, reflecting the heterogeneity in PRP preparation. (Dubin et al., 2024, J Am Acad Orthop Surg, PMID: 38295392)
The Rheumatology textbook notes that two recent placebo-controlled trials (one in knee OA, one in ankle OA) actually failed to show efficacy, highlighting that heterogeneous PRP preparation remains a major confounder.
- Rheumatology, 2-Volume Set (Elsevier, 2022), Chapter on OA therapeutics
4. Tendon-to-Bone Healing and Rotator Cuff Repair
PRP is being actively studied as an adjunct at the tendon-bone interface - a notoriously difficult healing environment. Campbell's lists PRP among multiple biologic modalities (alongside osteoinductive growth factors, periosteal grafts, biodegradable scaffolds, ultrasound, and shockwave therapy) under investigation for improving tendon-to-bone integration. Short-term positive effects have been reported in arthroscopic rotator cuff repair studies, but evidence remains preliminary.
- Campbell's Operative Orthopaedics, 15th ed. (2026), Chapter 2
5. Osteochondral Lesions
A meta-analysis found PRP beneficial for improving functional outcome scores in osteochondral lesions of the talus at 7-42 months of follow-up, with or without concomitant microfracture.
- Rockwood and Green's Fractures in Adults, 10th ed. (2025)
PRP Preparation and Classification
The lack of standardization is the single biggest limitation in interpreting PRP research. Key variables include:
| Variable | Options |
|---|---|
| Leukocyte content | Leukocyte-rich (LR-PRP) vs. leukocyte-poor (LP-PRP) |
| Platelet concentration | 2x to 10x baseline |
| Activation | Thrombin, calcium chloride, or none |
| Delivery method | Injection, intraoperative application, scaffold impregnation |
| Number of injections | Single vs. serial (typically 1-3) |
Leukocyte-rich PRP is more pro-inflammatory and may be preferable for tendon indications; leukocyte-poor PRP may be better for intra-articular OA use. No universal classification is in widespread clinical use, though the PAD (Platelet, Activation, Delivery) and PLRA (Platelets, Leukocytes, Red cells, Activation) systems have been proposed.
Adverse Effects
PRP is generally well-tolerated. Known issues include:
- Post-injection flare (transient pain/swelling, days 1-3) - especially with leukocyte-rich formulations
- Infection risk - very low but present with any injection
- No significant increase in adverse events compared to placebo or active comparators in large trials
Current Limitations
- Preparation heterogeneity - platelet concentration, leukocyte content, and activation method vary enormously across studies
- Lack of large multicenter RCTs for most indications
- Placebo effect - injections carry an inherent placebo component
- Cost and coverage - PRP is often not reimbursed by insurance in many countries, as regulatory bodies have not uniformly approved it
- Long-term data - beyond 12 months, evidence is sparse for most conditions
Summary Table
| Indication | PRP Evidence | Strength |
|---|---|---|
| Knee osteoarthritis | Superior to CS/HA at 3-12 months | Moderate-strong |
| Lateral epicondylitis | Superior to CS at 3-12 months | Moderate |
| Plantar fasciitis | Superior to CS at 6 months | Moderate |
| Rotator cuff tendinopathy | Superior to CS at 3 months | Moderate |
| Osteochondral lesions (talus) | Beneficial at 7-42 months | Moderate |
| Achilles rupture (non-surgical) | No benefit vs. placebo | Negative evidence |
| Tendon-to-bone healing (surgical) | Under investigation | Preliminary |
PRP occupies a growing but contested space in orthopedic practice. The most defensible current position is that it offers durable mid-term benefit over corticosteroids for tendinopathies and knee OA, but standardization of preparation and larger definitive trials are still needed before universal clinical guidelines can be established.
This is a shared conversation. Sign in to Orris to start your own chat.